<DOC>
	<DOC>NCT00576706</DOC>
	<brief_summary>To prove that the efficacy and safety of Mucosta® (Rebamipide) is non-inferior to those of Cytotec® (Misoprostol), in terms of prevention of NSAID-induced gastric ulcer.</brief_summary>
	<brief_title>PReventive Efficacy and Safety of rEbamipide on Nsaid Induced Mucosal Toxicity</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Rebamipide</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<criteria>1. Signed written informed consent after being informed of the clinical trial 2. Males or females 19 years of age 3. Intake of any brand of NSAIDs in more than half of daily dose for at least the previous 4 weeks. 1. Necessary to proceed in concomitant treatment with epileptic medications, antichollinergics, prokinetics, sucralfate 2. Presence or history of allergic drug reaction to the following medications; rebamipide, Misoprostol, NSAIDs designated to the protocol</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Patients with rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis or any other arthritis-like disease requiring continuous NSAIDs therapy</keyword>
</DOC>